<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Sickle cell disease in sub-Saharan Africa
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Sickle cell disease in sub-Saharan Africa
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Sickle cell disease in sub-Saharan Africa
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael R DeBaun, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Najibah A Galadanci, PhD, MBBS, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elliott P Vichinsky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 09, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H432682206">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of individuals with sickle cell disease (SCD) are born in sub-Saharan Africa, where easy access to high-intensity medical care may be limited to varying degrees.
        </p>
        <p>
         This topic discusses the challenges of SCD care in sub-Saharan Africa and a general approach to providing comprehensive care for patients with SCD in resource-poor settings.
        </p>
        <p>
         Additional topic reviews discuss overviews of the management of SCD in resource-rich settings. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14519.html" rel="external">
          "Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12698496">
         <span class="h1">
          PUBLIC HEALTH BURDEN OF SCD
         </span>
         <span class="headingEndMark">
          —
         </span>
         The greatest burden of SCD is in sub-Saharan Africa, where access to medical care and public health strategies to decrease mortality and morbidity are not uniformly available [
         <a href="#rid1">
          1-5
         </a>
         ]. Over 300,000 babies are born with SCD annually; this number is expected to increase to up to 400,000 individuals by 2050 [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The World Health Organization and United Nations have designated SCD as a global public health problem [
         <a href="#rid6">
          6,7
         </a>
         ]. One of the World Federation of Public Health Associations millennium development goals was targeted at reducing child mortality by two-thirds between 1990 and 2015 [
         <a href="#rid8">
          8
         </a>
         ]. Despite the major interventions in malaria, HIV, and immunization, most of the 19 countries estimated to have a persistently high mortality rate in individuals &lt;5 years old by 2015 (above 50 per 1000) are in Africa. We believe that the high prevalence of undiagnosed non-communicable diseases, including SCD, contribute to excess mortality in children under five years.
        </p>
        <p>
         Nearly 90 percent of the world's SCD population lives in three countries: Nigeria, India, and the Democratic Republic of Congo  (
         <a class="graphic graphic_figure graphicRef106077" href="/z/d/graphic/106077.html" rel="external">
          figure 1
         </a>
         ), where the disease affects up to 2 percent of the population, and the carrier prevalence rate (sickle cell trait) is as high as 10 to 30 percent [
         <a href="#rid3">
          3,4,9,10
         </a>
         ]. Nigeria alone has been estimated to have at least 150,000 newborns born with SCD annually. Estimates are challenging because of the lack of federal newborn screening programs; however, approximately 700,000 births occur per year and the prevalence of SCD in newborns was 3 percent in a regional newborn screening program [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
         The regions of Africa with a high incidence of SCD are also associated with the highest density of malaria [
         <a href="#rid13">
          13,14
         </a>
         ]. Although the sickle mutation at one allele of the beta globin gene (heterozygosity) confers a survival advantage in malaria endemic areas, especially for children, inheritance of the mutation at both alleles (Hb SS) predisposes individuals to severe malaria and increased malaria mortality, as well as increased mortality from other complications of SCD [
         <a href="#rid15">
          15,16
         </a>
         ]. The role of heterozygosity for the sickle mutation in protection from falciparum malaria is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7099.html" rel="external">
          "Protection against malaria by variants in red blood cell (RBC) genes", section on 'Sickle cell variant'
         </a>
         .)
        </p>
        <p>
         In high-income countries, the survival of individuals with SCD has been steadily increasing, often well into adulthood (see
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Overall survival'
         </a>
         ). In contrast, a study from 2011 reported SCD-related childhood mortality in Africa as high as 50 to 90 percent, with fewer than one-half of affected children reaching their fifth birthday [
         <a href="#rid17">
          17
         </a>
         ]. A multicenter case-control study from 2022 assessed 1563 children with SCD and 4972 children without SCD living in the same neighborhood, using data from five countries in sub-Saharan Africa, and found the following mortality rates [
         <a href="#rid18">
          18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;1 year – 15.3 percent (95% CI 13.3-17.3)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;5 years – 36.4 percent (95% CI 33.4-39.4)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;10 years of age – 43.3 percent (95% CI 39.3-47.3)
        </p>
        <p>
        </p>
        <p>
         These mortality rates were lower than the prior study from 2011 [
         <a href="#rid17">
          17
         </a>
         ]; the differences may be related to variations in methodology.
        </p>
        <p class="headingAnchor" id="H243649">
         <span class="h1">
          OVERVIEW OF MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Simple public health measures, such as newborn screening and parental/caregiver education on how to detect splenic sequestration and when to bring a febrile child to medical attention, can have a dramatic impact on survival in children with SCD living in resource-poor countries [
         <a href="#rid19">
          19
         </a>
         ]. Generally, the principles of management are as follows; these are discussed in more detail in the sections below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identification of newborns with SCD as soon after birth as possible (before the development of complications) – (See
         <a class="local">
          'Identifying individuals with SCD'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Education regarding when to seek medical attention – (See
         <a class="local">
          'Education'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of infection (vaccinations, penicillin prophylaxis, and malaria prophylaxis) – (See
         <a class="local">
          'Bacterial infections (prophylaxis)'
         </a>
         below and
         <a class="local">
          'Malaria (prophylaxis)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prompt treatment of infections, especially invasive bacterial infections and malaria – (See
         <a class="local">
          'Bacterial infections (treatment)'
         </a>
         below and
         <a class="local">
          'Malaria (treatment)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adequate pain control and hydration for vaso-occlusive pain – (See
         <a class="local">
          'Pain episodes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When possible,
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         to reduce the risk of vaso-occlusive complications, especially primary and secondary stroke prevention, administered at a fixed-dose with monitoring as discussed below – (See
         <a class="local">
          'Stroke'
         </a>
         below and
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reserving blood transfusions for life-threatening anemia – (See
         <a class="local">
          'Blood transfusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring for chronic complications such as stroke, kidney disease, pulmonary hypertension, and asthma/chronic lung disease; and close monitoring during pregnancy – (See
         <a class="local">
          'Primary and secondary prevention (stroke)'
         </a>
         below and
         <a class="local">
          'Complications affecting the kidney'
         </a>
         below and
         <a class="local">
          'Pulmonary complications'
         </a>
         below and
         <a class="local">
          'Pregnancy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Of these, the most important are prophylaxis against bacterial infections and malaria, prompt treatment of acute bacterial and malarial infection, pain control, and limiting blood transfusion to severe, life-threatening anemia. Observational studies in resource-poor countries such as Benin and Nigeria have demonstrated that these simple measures can reduce morbidity and mortality [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         The major challenges to implementing comprehensive care in sub-Saharan Africa include poverty, lack of universal health insurance in most countries, limited number of specialized care facilities located primarily in large cities, limited number of trained health care personnel, limited access to the technologies required to provide evidence-based medical care, and limited access to disease modifying therapies produced on the continent at an affordable cost, except for
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         which is produced in Nigeria below cost.
        </p>
        <p>
         Our approach is consistent with strategies published by the World Health Organization (WHO), which identified the need for primary prevention of SCD, SCD screening in newborn period, genetic counseling, and accessible comprehensive care [
         <a href="#rid22">
          22
         </a>
         ]. The specific objectives of the WHO regional meeting included identifying priority interventions for member states to develop and implement, programs and policies for SCD prevention and control at all levels, and establishing mechanisms for monitoring, evaluation, and research on SCD in African countries. Partnerships between centers in different parts of the world (so-called "North-South partnerships") may be a useful strategy for facilitating these goals [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H432682475">
         <span class="h1">
          IDENTIFYING INDIVIDUALS WITH SCD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early diagnosis of SCD improves survival. However, only a few centers in sub-Saharan Africa are able to initiate newborn screening and deliver comprehensive health care at an early age [
         <a href="#rid9">
          9,24
         </a>
         ]. Most other individuals are diagnosed when they present with a complication of disease.
        </p>
        <p class="headingAnchor" id="H4201262117">
         <span class="h2">
          Available diagnostic tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typically, hemoglobin electrophoresis is used to make the diagnosis in individuals suspected to have SCD based on clinical features and review of the blood smear. High performance liquid chromatography (HPLC) is used in some centers to confirm the diagnosis, depending on availability.
        </p>
        <p>
         Point-of-care (POC) diagnostic testing for SCD is under development; some of the tests are summarized in the table  (
         <a class="graphic graphic_table graphicRef115905" href="/z/d/graphic/115905.html" rel="external">
          table 1
         </a>
         ). Once they become available, these tests may be especially useful in areas where it is not possible or convenient to transfer blood samples to a centralized laboratory.
        </p>
        <p>
         Additional details about these diagnostic tests are presented in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/13941.html" rel="external">
          "Methods for hemoglobin analysis and hemoglobinopathy testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12698876">
         <span class="h2">
          Newborn screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnosis of SCD early in life improves survival. Early diagnosis allows for initiation of well-established public health measures for primary prevention including penicillin prophylaxis, routine childhood vaccinations, parental/caregiver education about prompt medical management for fever, and detection of splenic sequestration. These strategies have been demonstrated to minimize morbidity and improve outcomes and are the basis for newborn screening for SCD being performed in every state in the United States [
         <a href="#rid25">
          25
         </a>
         ]. However, laboratory methods for diagnosis require an infrastructure that is not routinely available in sub-Saharan Africa. Only a few centers in sub-Saharan Africa are able to initiate newborn screening and deliver comprehensive health care at an early age due to the costs associated with such programs [
         <a href="#rid9">
          9,24
         </a>
         ].
        </p>
        <p>
         The importance of newborn screening in reducing mortality has been demonstrated in the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          United States
         </strong>
         – Reduced mortality was reported in a review that summarized 10 years of experience using newborn screening in the state of California from 1975 to 1985 [
         <a href="#rid26">
          26
         </a>
         ]. Of over 80,000 newborns screened, SCD was diagnosed in approximately 0.1 percent and sickle cell trait in 2.6 percent. Mortality in the 81 patients diagnosed with SCD by newborn screening (coupled with education about detecting splenic sequestration and early warning signs of infection) was 1.8 percent over seven years, dramatically lower than the 8 percent mortality in a comparison group of patients diagnosed after three months of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Africa
         </strong>
         – In a program in Kenya that identified infants with and without SCD in infancy and then followed them over several years, the survival difference was about the same in those with hemoglobin SS and normal hemoglobin and much higher in children with hemoglobin AS [
         <a href="#rid27">
          27
         </a>
         ]. Modeling simulations also suggest that universal screening is especially cost effective in populations with a high frequency of the prevalence of SCD &gt;0.2 to 0.5 per 1000 births [
         <a href="#rid28">
          28
         </a>
         ]. The threshold for screening for SCD (0.5 per 1000 births) in many countries in Africa far exceeds the minimum threshold for cost-effectiveness for newborn screening. As an example, in Nigeria the rate of SCD is estimated to be 30 per 1000 births (3 percent) [
         <a href="#rid12">
          12
         </a>
         ]. No federal newborn screening program for SCD has been established for any country in sub-Saharan Africa despite the clear economic and humanitarian basis for such programs; Ghana is close to implementing such a program.
        </p>
        <p>
        </p>
        <p>
         The American Society of Hematology (ASH) has instituted the Consortium on Newborn Screening in Africa (CONSA) for SCD, a seven-country network of sites including Ghana, Kenya, Liberia, Nigeria, Uganda, Tanzania, and Zambia [
         <a href="#rid29">
          29
         </a>
         ]. The main objectives are to establish universal screening and early interventions for SCD within clinical networks of CONSA partners and to assess clinical trial implementation. All seven countries have successfully launched their programs. Rapid, easy to use, accurate, and inexpensive point-of-care (POC) testing may be the key to making widespread screening possible and efficient. The most commonly used POC tests in Africa include the HemoTypeSC and Sickle SCAN [
         <a href="#rid30">
          30-33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13941.html" rel="external">
          "Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Point-of-care assays'
         </a>
         .)
        </p>
        <p>
         Several studies in multiple African countries including Nigeria, Mali, Ghana, and Cote D Ivoire have shown that POC tests are accurate and reliable in detecting SCD with high sensitivity and specificity. However, the cost of these POC tests may be high, approaching the cost of HPLC. (See
         <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">
          "Diagnosis of sickle cell disorders", section on 'Newborn screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H244521">
         <span class="h2">
          Childhood presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most individuals in sub-Saharan Africa with SCD are not diagnosed by newborn screening and present with symptoms during childhood, at a mean age of two years. Very few are diagnosed during infancy. The most common presentations for previously undiagnosed SCD include dactylitis at six months to one year of age and splenic sequestration in the second year of life. Thus, we believe that children presenting with either dactylitis or splenic sequestration should be evaluated for SCD with a complete blood count (CBC) and hemoglobin analysis. (See
         <a class="local">
          'Available diagnostic tests'
         </a>
         above.)
        </p>
        <p>
         As part of the Transfusion and Treatment of severe anemia in African Children Trial (TRACT; ISRCTN84086586), the investigators developed a diagnostic algorithm to identify SCD among all children admitted with severe anemia to African hospitals [
         <a href="#rid34">
          34
         </a>
         ]. The algorithm included children &lt;12 months of age with severe anemia, gross splenomegaly, negative malaria testing, high white blood count (WBC), higher mean corpuscular volume (MCV+), low platelet count, and family history of SCD. Based on the algorithm, they were able to detect 73 percent of all children with unknown SCD, with a number needed to test to identify one new SCD case of only two.
        </p>
        <p class="headingAnchor" id="H1806322">
         <span class="h1">
          EDUCATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         All families in areas where SCD is endemic, especially those in which a family member has SCD, should be aware of common presenting findings of SCD and should understand the importance of being evaluated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parents/caregivers of infants and young children with SCD are educated about the importance of prophylaxis and treatment of infections (see
         <a class="local">
          'Infections'
         </a>
         below):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infection prevention, which includes vaccinations and prophylactic penicillin to prevent bacterial infections, and mosquito netting and malaria prophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prompt treatment of infection, including when to bring an ill infant or child to medical attention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children and adults should be educated about the presenting symptoms of acute chest syndrome, splenic sequestration, and stroke. All patients should understand the use of transcranial Doppler screening (TCD), and those with prior stroke or elevated TCD measurement should understand the potential benefits (and risks) of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         therapy. (See
         <a class="local">
          'Vaso-occlusive events'
         </a>
         below and
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals of childbearing age should be educated about risks of having an affected child, and those who become pregnant should understand the importance of appropriate prenatal care,
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         supplementation, and adequate hydration. Vaginal delivery should be targeted to 38 weeks gestation if possible. (See
         <a class="local">
          'Pregnancy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults should be counseled about possible chronic complications including renal, pulmonary, and orthopedic complications and available interventions to minimize morbidity. (See
         <a class="local">
          'Chronic complications/adults'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12701445">
         <span class="h1">
          INFECTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1808908">
         <span class="h2">
          Bacterial infections
         </span>
        </p>
        <p class="headingAnchor" id="H3912334275">
         <span class="h3">
          Bacterial infections (epidemiology and causes)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of bacterial infection is dramatically increased in SCD, particularly for children less than five years of age [
         <a href="#rid35">
          35
         </a>
         ]. This is especially true for encapsulated organisms because most patients become functionally asplenic early in life (eg, within the first year) due to repeated episodes of sickling-induced splenic infarction [
         <a href="#rid36">
          36
         </a>
         ]. Additional contributing factors include abnormalities of opsonization, antibody production, the alternate complement pathway, leucocyte function defects, and cell-mediated immunity [
         <a href="#rid37">
          37-39
         </a>
         ].
        </p>
        <p>
         The increased incidence of bacterial infection in African populations with SCD was illustrated in a 2010 review of case-control or cohort studies that described bacteremia, meningitis, or pneumonia in patients with or without SCD [
         <a href="#rid40">
          40
         </a>
         ]. The pooled odds ratio of invasive bacterial infection associated with SCD was 19 (95% CI 15-24).
        </p>
        <p>
         The most common bacterial organisms in individuals with SCD include
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          H. influenzae
         </em>
         type b, and non-typhoid salmonellosis [
         <a href="#rid39">
          39,41,42
         </a>
         ]. Children under five years of age are at greatest risk for meningitis and septicemia, while all age groups may develop salmonella osteomyelitis [
         <a href="#rid39">
          39,43
         </a>
         ]. The infections seen in Africa are similar to those seen in the United States prior to the institution of routine penicillin prophylaxis and vaccination for encapsulated organisms in the mid-1980s in children with SCD.
        </p>
        <p>
         Asymptomatic bacteriuria (ASB) is more common in individuals with SCD compared with those without, although its significance is unclear. This was demonstrated in a 2017 study from Ghana that found a prevalence of ASB of 17 percent in individuals with SCD, compared with 8 percent in the control group [
         <a href="#rid44">
          44
         </a>
         ]. ASB was found to be higher among females, and the spectrum of organisms and etiology of ASB in the SCD patients was more diverse compared with controls.
        </p>
        <p class="headingAnchor" id="H3874632693">
         <span class="h3">
          Bacterial infections (treatment)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parents/caregivers should bring children to medical attention if they have definite or possible indications of infection. Definite indications of infection include fever, tachycardia, and hypotension; along with signs and symptoms suggestive of acute chest syndrome (eg, cough, chest pain), meningitis (eg, headache, nuchal rigidity, altered mental status)  (
         <a class="graphic graphic_table graphicRef105545" href="/z/d/graphic/105545.html" rel="external">
          table 2
         </a>
         ), or acute osteomyelitis (eg, bone pain, tenderness, limited range of motion). Very young infants may not complain about pain but may show decreased alertness or appetite and will exhibit tenderness of the affected extremities.
        </p>
        <p>
         Laboratory evaluation includes complete blood count, blood and urine cultures, and chest radiography. Lumbar puncture with cerebrospinal fluid analysis and cultures are done for patients with concern for meningitis.
        </p>
        <p>
         Patients with these findings should be treated promptly with broad-spectrum antibiotics. Common treatment of bacterial infections involves oral or intravenous antibiotics, generally selected based on known efficacy against likely causative organisms. Intravenous antibiotics are generally reserved for individuals who are acutely ill and hospitalized. Practice patterns may vary based on hospital resources but are generally similar to that used for asplenic individuals in other settings.
        </p>
        <p class="headingAnchor" id="H1808631">
         <span class="h3">
          Bacterial infections (prophylaxis)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two major interventions to reduce the incidence of bacterial infections are vaccinations, especially against encapsulated organisms, and penicillin prophylaxis. However, the availability of vaccinations is limited, and routine penicillin prophylaxis is unavailable in the majority of medical centers in sub-Saharan Africa [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccinations
         </strong>
         – We strongly believe that integration of routine childhood immunization against
         <em>
          Streptococcus pneumoniae
         </em>
         and
         <em>
          Haemophilus influenzae
         </em>
         into the standard of care in sub-Saharan African countries could substantially affect survival of children with SCD [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The administration of childhood vaccinations has been shown to lead to a remarkable decrease in the overall morbidity and mortality associated with infection in children with SCD. This is especially true for invasive pneumococcal disease and
         <em>
          H. influenzae
         </em>
         . This was demonstrated in a 2016 retrospective study that analyzed a cohort of children with SCD living in Gambia over a five-year period [
         <a href="#rid46">
          46
         </a>
         ]. During the study period, there was a high level of coverage with
         <em>
          Haemophilus influenzae
         </em>
         type b (Hib) and pneumococcal conjugate vaccinations. The most frequent blood-borne isolate was
         <em>
          Salmonella typhimurium
         </em>
         , followed by
         <em>
          Staphylococcus aureus
         </em>
         and other enteric Gram-negative pathogens, with no bacteremia by caused by
         <em>
          S. pneumoniae
         </em>
         or
         <em>
          H. influenzae
         </em>
         . The low prevalence of
         <em>
          S. pneumoniae
         </em>
         and
         <em>
          H. influenzae
         </em>
         indicated that the conjugated vaccines can significantly decrease the rate of bacteremia in children with SCD in sub-Saharan Africa. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Pneumococcal disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">
          "Prevention of
          <i>
           Haemophilus influenzae
          </i>
          type b infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, the conjugated vaccines against these organisms such as the heptavalent conjugate pneumococcal vaccine (PCV7), which offers protection against invasive pneumococcal infections, and the
         <em>
          H. influenzae
         </em>
         type b conjugate vaccine, which offers protection against meningitis and septicemia caused by
         <em>
          H. influenzae
         </em>
         , are only available in some medical centers in sub-Saharan Africa. Even when available, they are unaffordable to the majority of families.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Penicillin
         </strong>
         – Penicillin prophylaxis is highly effective in preventing infection. We recommend monthly intramuscular penicillin prophylaxis rather than daily oral penicillin, based on evidence that adherence to oral penicillin is only 50 to 60 percent [
         <a href="#rid47">
          47,48
         </a>
         ]. In contrast, adherence to monthly intramuscular penicillin is approximately 88 percent [
         <a href="#rid49">
          49
         </a>
         ]. Use of intramuscular penicillin also avoids the requirement for refrigeration of oral penicillin suspension, which may be challenging in low-income countries. We continue penicillin prophylaxis until age five years if possible, and some pediatricians may elect to continue for a longer period of time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, routine penicillin prophylaxis is unavailable in the majority of medical centers.
        </p>
        <p>
        </p>
        <p>
         Additional information about the efficacy of these interventions and typical schedules are presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Infection prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H52222">
         <span class="h2">
          Malaria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malaria infection in individuals with homozygous sickle hemoglobin S (Hb SS) is one of the most common causes of vaso-occlusive pain, one of the leading reasons for hospitalization, and one of the most important causes of mortality in sub-Saharan Africa, despite the evidence that Hb SS improves mortality in children &lt;5 years [
         <a href="#rid27">
          27,50,51
         </a>
         ]. The first five years of life are the highest risk for malaria because of the lack of immunity, regardless of the hemoglobin type (hemoglobin SS, AS, or AA) [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         As discussed below, a randomized trial showed that administration of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         did not increase the risk of malaria infection. (See
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H204671">
         <span class="h3">
          Malaria (prophylaxis)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Strategies for control and prevention of malaria include mosquito control, personal protection, and antimalarial prophylaxis.
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         is not a form of prophylaxis, but it does decrease malaria risk, as discussed below. (See
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p>
         For prophylaxis, we prefer daily proguanil (100 mg daily). This is based on our experience that patients are more likely to take this once daily medication with a single agent, and the lower frequency of side effects compared with intermittent therapy. Other possible regimens include [
         <a href="#rid15">
          15,20,53,54
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proguanil 100 mg daily (preferred, as noted above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          Chloroquine
         </a>
         5 mg/kg every other day
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          Pyrimethamine
         </a>
         weekly
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sulfadoxine-pyrimethamine monthly
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermittent therapy with one of the following [
         <a href="#rid55">
          55
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Combination of
         <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">
          mefloquine
         </a>
         (MQ) with
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         (AS)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Combination of sulfadoxine-pyrimethamine (SP) with amodiaquine (AQ)
        </p>
        <p>
        </p>
        <p>
         The risk of malaria in Africa was shown to be decreased with antimalarial prophylaxis using
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         5 mg/kg every two days, proguanil 100 mg daily, weekly
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         or monthly sulfadoxine-pyrimethamine; along with the regular use of insecticide-treated bed nets [
         <a href="#rid15">
          15,20,53,54
         </a>
         ].
        </p>
        <p>
         Intermittent preventive therapy was demonstrated to have superior efficacy to (and to be better tolerated than) daily prophylaxis in a trial involving 270 children with SCD in Nigeria [
         <a href="#rid55">
          55
         </a>
         ]. Intermittent therapy involved administration once every two months of either MQ with AS for three days (MQAS) or SP for one day plus AQ for three days (SPAQ). Compared with daily proguanil, both intermittent therapy regimens were associated with a lower incidence of malaria (events per person-year: proguanil, 0.20; MQAS, 0.08; SPAQ, 0.13); however, a similar number of hospital admissions was seen for all groups. Adherence to intermittent therapy (administered at clinic visits) was excellent; in contrast, pill counts suggested that 57 percent of patients assigned to daily proguanil took &lt;75 percent of their daily doses. Serious adverse events were low in all groups (&lt;1 percent); vomiting, body pain, and abdominal pain were more frequent with MQAS and SPAQ than with proguanil. However, as noted above, based on our experience we prefer daily single agent therapy due to its lower frequency of side effects and our impression of improved adherence.
        </p>
        <p>
         Personal protection with insecticide-treated bed nets and mosquito repellents has shown varying success rates in malaria endemic areas in sub-Sahara Africa [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Malaria risk (likelihood of infection and/or severity) may be reduced in individuals taking
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         . (See
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p>
         Additional information about these approaches, as well as a discussion about vaccine development, is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5702.html" rel="external">
          "Malaria: Epidemiology, prevention, and control"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432682583">
         <span class="h3">
          Malaria (treatment)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prompt initiation of malaria treatment is important both for managing the infection as well as treating or reducing the associated manifestations of SCD such as vaso-occlusive pain and worsening hemolytic anemia.
        </p>
        <p>
         In children with SCD, malaria infection is associated with severe hemolysis and typically presents with fever, brown-colored urine, acute fatigue, and vaso-occlusive pain. In adults with SCD, malaria infection causes a similar clinical presentation and is associated with vaso-occlusive pain episodes [
         <a href="#rid57">
          57,58
         </a>
         ]. Thus, prompt initiation of antimalarial therapy among acutely ill patients with SCD and confirmed malaria infection is important in the management of both conditions [
         <a href="#rid57">
          57-59
         </a>
         ].
        </p>
        <p>
         The two most commonly used first-line antimalarial therapies in sub-Saharan Africa include the combination of artesunate-amodiaquine and the combination of
         <a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">
          artemether-lumefantrine
         </a>
         [
         <a href="#rid59">
          59
         </a>
         ]. These therapies have been shown to be efficacious and associated with relatively few and rare side effects [
         <a href="#rid59">
          59,60
         </a>
         ]. Other artemisinin-based combinations used for treatment of acute malaria include artesunate-amodiaquine, dihydroartemisinin-piperaquine, chlorproguanil-dapsone-artesunate, artesunate-mefloquine, and artesunate-azithromycin [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         These and other malaria treatment regimens are summarized in the tables and presented in more detail separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe falciparum malaria (or species unknown)  (
         <a class="graphic graphic_table graphicRef79194" href="/z/d/graphic/79194.html" rel="external">
          table 3
         </a>
         ) – (See
         <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">
          "Treatment of severe malaria"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncomplicated falciparum malaria  (
         <a class="graphic graphic_table graphicRef72019" href="/z/d/graphic/72019.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef96455" href="/z/d/graphic/96455.html" rel="external">
          table 5
         </a>
         ) – (See
         <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">
          "Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncomplicated non-falciparum malaria  (
         <a class="graphic graphic_table graphicRef67642" href="/z/d/graphic/67642.html" rel="external">
          table 6
         </a>
         ) – (See
         <a class="medical medical_review" href="/z/d/html/5706.html" rel="external">
          "Non-falciparum malaria: P. vivax, P. ovale, and P. malariae"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12700251">
         <span class="h2">
          HIV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human immunodeficiency virus (HIV) infection and SCD are considered to be endemic in some regions of Africa. Moreover, as noted in a systematic review, HIV and SCD both are associated with stroke, avascular necrosis of bone, severe splenic dysfunction, pulmonary hypertension, and sepsis, and their coexistence may synergize in increasing the risks of these SCD complications [
         <a href="#rid62">
          62
         </a>
         ]. Other studies have shown that HIV infection in individuals with SCD is associated with an increased risk of pneumococcal infection [
         <a href="#rid63">
          63
         </a>
         ]. At the same time, HIV infection may blunt the response to vaccination against pneumococcus.
        </p>
        <p>
         Management of concomitant HIV and SCD presents challenges, especially in sub-Saharan Africa where the level of care is suboptimal [
         <a href="#rid64">
          64,65
         </a>
         ]. Attention should be paid to the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In areas with a high prevalence of HIV, families and patients should receive education about the importance of early detection and prompt treatment of infections, particularly those caused by pneumococcus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Attention should be paid to potential interactions between HIV and SCD (eg, in increasing the risk for stroke, avascular necrosis, splenic dysfunction, pulmonary hypertension, and sepsis) [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12700062">
         <span class="h1">
          VASO-OCCLUSIVE EVENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaso-occlusive events in SCD include acute painful episodes and organ-specific complications such as stroke, acute chest syndrome (ACS), priapism, and dactylitis. (See
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12701645">
         <span class="h2">
          Pain episodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Painful episodes are a significant cause of morbidity, accounting for a large number of emergency department visits and hospital admissions [
         <a href="#rid66">
          66
         </a>
         ]. In many of the health facilities in sub-Saharan Africa, opioid analgesics are not readily available to patients, with the majority of these centers dependent on only nonsteroidal anti-inflammatory drugs (NSAIDs) and some non-opioid analgesics, leading to inadequate management of pain [
         <a href="#rid67">
          67
         </a>
         ]. Adequate hydration should be provided, including increased oral fluid intake at home and intravenous fluids if hospital admission is required.
        </p>
        <p>
         Dactylitis is the first presentation of pain in children with SCD. When dactylitis is present, management should be identical to those provided in high-income countries. This involves supportive care that includes hydration, NSAIDs and/or opioid analgesics, and assessment for occult infection, particularly bacteremia and malaria.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         has been demonstrated to reduce the frequency of acute painful events in SCD. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Indications and evidence for efficacy'
         </a>
         .)
        </p>
        <p>
         Although use in sub-Saharan Africa poses numerous additional challenges, we suggest
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         treatment in individuals with significant vaso-occlusive pain episodes (eg, three or more severe acute painful episodes per year), as long as appropriate monitoring can be performed, as discussed below. (See
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12700096">
         <span class="h2">
          Acute chest syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute chest syndrome (ACS) is one of the life-threatening vaso-occlusive complications seen both in children and adults with SCD. ACS is associated with high mortality rate, especially in sub-Saharan Africa and other low-income countries.
        </p>
        <p>
         The diagnosis of ACS in a high-income setting often relies on radiologic features of a new pulmonary radiodensity on chest radiograph and the use of pulse oximetry. However, pulse oximetry is not available in some medical centers. Therefore, the majority of clinicians rely on their clinical judgment for diagnosing ACS, which typically is based on fever, pain, and increased respiratory effort.
        </p>
        <p>
         The Ghana combined obstetric and SCD clinic has operationalized a definition of ACS in low-income settings where the cost of a chest radiograph may be beyond reach for many families. Specifically, the definition includes the following [
         <a href="#rid68">
          68,69
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of at least two of the following criteria, including positive chest signs:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Temperature &gt;38⁰C
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased respiratory rate of &gt;20 per minute
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive chest pain
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive findings on pulmonary auscultation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased oxygen requirement (SpO
         <sub>
          2
         </sub>
         drop by &gt;3 percent from a documented steady-state value on room air)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence or absence of new radiodensity on chest roentgenogram
        </p>
        <p>
        </p>
        <p>
         Typically, patients with this constellation of findings are treated with a broad-spectrum antibiotic to cover encapsulated organisms and a macrolide antibiotic to cover mycoplasma and chlamydia. Additional interventions include pain control (generally using NSAIDs) and hydration, along with supplementary oxygen and/or blood transfusion, if needed and available [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Additionally, a feasibility trial in northern Nigeria indicated that fixed-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         (approximately 20 mg/kg/day) is an alternative to initial regular blood transfusion therapy [
         <a href="#rid70">
          70
         </a>
         ]. Hydroxyurea has been demonstrated to reduce the frequency of ACS in SCD. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Indications and evidence for efficacy'
         </a>
         .)
        </p>
        <p>
         Uniform access to
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         in sub-Saharan Africa poses numerous additional challenges. (See
         <a class="local">
          'Access to stroke prevention interventions'
         </a>
         below.)
        </p>
        <p>
         Despite financial and laboratory monitoring challenges, we suggest administration of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         in individuals with either a single episode of life-threatening ACS that requires exchange transfusions or repeated significant episodes of ACS that require regular blood transfusion therapy, as long as appropriate monitoring can be performed, as discussed below. (See
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12700116">
         <span class="h2">
          Splenic sequestration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Splenic sequestration is a potentially life-threatening complication that occurs when blood pools rapidly in the spleen. Splenic sequestration is characterized by an acute fall in the hemoglobin level accompanied by a rapidly enlarging spleen or liver (&gt;2 cm increase from the steady-state level) and increased reticulocytosis above the steady-state level. In some cases, splenic sequestration may be associated with malaria or another infection, particularly parvovirus B19 [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Management of splenic sequestration in resource-limited settings involves hospital admission with urgent laboratory testing (complete blood count [CBC], pretransfusion testing) and blood transfusion at a dose of 5 mL/kg (this is 50 percent of the typical amount, due to the risk of autotransfusion of red blood cells that were pooled in the spleen, which may result in life-threatening hyperviscosity syndrome) [
         <a href="#rid72">
          72
         </a>
         ]. In some centers, exchange transfusion may be performed if feasible.
        </p>
        <p>
         Repeated episodes of splenic sequestration are common, especially in malaria-endemic regions, and measures to reduce splenic sequestration are advisable. For patients who have had one or more episodes of splenic sequestration, splenectomy may be appropriate. We generally advise splenectomy following the first episode of splenic sequestration. There is no evidence that regular blood transfusion therapy prevents recurrent splenic sequestration [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         In contrast, there is little evidence that regular blood transfusion or
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         therapy reduces the risk of splenic sequestration.
        </p>
        <p class="headingAnchor" id="H12700447">
         <span class="h2">
          Stroke
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with SCD are at increased risk of neurological complications including overt strokes and silent cerebral infarcts, both of which are associated with increased morbidity and mortality. Approximately 11 percent of children with SCD will have a stroke before age 18 without transcranial Doppler (TCD) screening and regular blood transfusions or low dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         therapy if TCD values are high. Without secondary prevention, more than one-half of these will have a recurrent stroke within two years of the initial stroke [
         <a href="#rid74">
          74,75
         </a>
         ]. (See
         <a class="local">
          'Primary and secondary prevention (stroke)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H86524397">
         <span class="h3">
          Acute management (stroke)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard radiologic imaging to determine the type of stroke is not available in the majority of medical centers in sub-Saharan Africa. Thus, diagnosis of stroke is made by clinical evaluation.
        </p>
        <p>
         Tools to help in making the clinical diagnosis of stroke include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of clinical features that may distinguish stroke from other neurologic complications of SCD such as cerebral malaria or bacterial meningitis  (
         <a class="graphic graphic_table graphicRef105545" href="/z/d/graphic/105545.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Pediatric NIH Stroke Scale (NIHSS)  (
         <a class="graphic graphic_table graphicRef76120" href="/z/d/graphic/76120.html" rel="external">
          table 7
         </a>
         ) or the adult scale for adults  (
         <a class="graphic graphic_table graphicRef61698" href="/z/d/graphic/61698.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Online videos (eg,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DgzHuNvDhVwE&amp;token=3BBziCZQDrEhIlt93szQloH6eZnp6PMXkxC7JnVMP%2FVamag4zdca9MBWiyBcbM%2FwcI5Lq7Ig%2FF3PyLYjLm%2BvBg%3D%3D&amp;TOPIC_ID=99489" target="_blank">
          http://www.youtube.com/watch?v=gzHuNvDhVwE
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Pediatric Stroke Outcome Measure (PSOM) [
         <a href="#rid76">
          76
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The standard management approach, including immediate blood transfusion followed by exchange blood transfusion to maintain the hemoglobin S (HbS) percentage below 30 percent, is not available in the majority of medical centers in sub-Saharan Africa [
         <a href="#rid77">
          77-80
         </a>
         ].
        </p>
        <p>
         Acute stroke management in resource-poor settings includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immediate admission into the hospital
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of vital signs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examination to assess the extent and severity of central nervous system involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance of airway and breathing, and oxygen administration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of laboratory values including evaluation for hypoglycemia, hyponatremia, and hypernatremia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of fever with antipyretics and presumptive treatment of infection with antibacterial and antimalarial agents until results of cultures are available (see
         <a class="local">
          'Bacterial infections (treatment)'
         </a>
         above and
         <a class="local">
          'Malaria (treatment)'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous fluids
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Simple blood transfusion when available
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Where available, simple blood transfusion is followed by modified- or full-exchange blood transfusion, performed either manually or automated [
         <a href="#rid81">
          81,82
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         As noted above, imaging of the brain is not routinely performed.
        </p>
        <p class="headingAnchor" id="H86524403">
         <span class="h3">
          Primary and secondary prevention (stroke)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regardless whether children live in low- or high-income settings, the risk of stroke in children with SCA is approximately 11 percent by 18 years of age [
         <a href="#rid74">
          74
         </a>
         ]. Further, once a child with SCA has a stroke, without treatment, approximately 50 percent will have second stroke [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         Taken together, these data provide compelling evidence for primary and secondary stroke prevention with
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         . Preliminary data indicate fixed dose of hydroxyurea is effective in decreasing both transcranial Doppler ultrasound (TCD) measurements from abnormal to normal and for primary prevention of strokes [
         <a href="#rid84">
          84-86
         </a>
         ]. Randomized controlled trials conducted in sub-Saharan Africa have also shown that hydroxyurea can be safely administered to children with abnormally high TCD measurements and effectively reduce TCD velocities [
         <a href="#rid84">
          84,87,88
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary prevention
         </strong>
         – Results of the SPRING (
         <strong>
          S
         </strong>
         troke
         <strong>
          P
         </strong>
         revention
         <strong>
          I
         </strong>
         n
         <strong>
          N
         </strong>
         i
         <strong>
          g
         </strong>
         eria) trial indicate that starting most children on low-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         (approximately 10 mg/kg daily) is an effective strategy for primary stroke prevention. (See
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         SPRING assessed the rate of stroke or transient ischemic attack in 220 children ages 5 to 12 years with SCD and abnormal TCD velocities who were randomly assigned to receive fixed low-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         (approximately 10 mg/kg daily) or fixed moderate-dose hydroxyurea (approximately 20 mg/kg daily) [
         <a href="#rid89">
          89
         </a>
         ]. An additional nine children crossed over from the control group to the hydroxyurea arms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The trial was stopped early at 3 years of follow-up due to the low rates of stroke in both groups. In the low-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         group (median dose, 10.8 mg/kg/day), 3 of 109 participants (3 percent) had strokes (incidence rate, 1.19 per 100 person-years). In the moderate-dose hydroxyurea group (median dose, 20.6 mg/kg/day), 5 of 111 participants (5 percent) had strokes (incidence rate, 1.92 per 100 person-years). The incidence rate ratio (IRR) showed a trend towards lower rates of stroke with low-dose hydroxyurea that was not statistically significant (IRR, 0.62 [95% CI 0.10-3.20], p = 0.77).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         that was locally manufactured in Nigeria and made available to participants at cost made the treatment feasible during the trial and made continued use sustainable after the trial ended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While initial stroke rates were not statistically different with low-dose versus moderate-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         in SPRING, hospitalization for any reason was more frequent in the low-dose group (27.43 per 100 person-years with low dose versus 16.08 with moderate dose; IRR 1.71, 95% CI 1.15-2.57, p = 0.0071). Moderate-dose hydroxyurea was also associated with a significant decrease in vaso-occlusive pain events at home. No participant had to stop hydroxyurea for myelosuppression. For children with prior or concurrent high rates of hospitalization or vaso-occlusive pain events, shared decision making should be done to decrease the SCD morbidity rate; otherwise, for primary stroke prevention, a fixed dose of 10 mg/kg daily should be considered, with a CBC two times a year for monitoring.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary prevention
         </strong>
         – The 2020 American Society of Hematology (ASH) guidelines for secondary prevention of stroke in people with SCD recommend that when initial regular blood transfusion therapy is not available, moderate-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         therapy (approximately 20 mg/kg/day) should be considered at a minimum [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The SPRINT trial (Stroke Prevention in Nigeria Trial) was published after the 2020 ASH guidelines. SPRINT randomly assigned 101 children with sickle cell anemia living in Nigeria to receive fixed oral moderate-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         (20 mg/kg daily) or fixed oral low-dose hydroxyurea (10 mg/kg daily) for 30 days [
         <a href="#rid91">
          91
         </a>
         ]. The trial was stopped due to no clinically meaningful difference in the incidence of recurrent strokes (7.1 and 6 per 100 person-years in the low- and moderate-dose groups, respectively; IRR 1.18, 95% CI 0.30-4.88). The authors concluded that for children with sickle cell anemia who are living in low-income settings without access to regular blood transfusion therapy, initial low-dose hydroxyurea is a minimum known effective dose for secondary stroke prevention.
        </p>
        <p>
        </p>
        <p>
         The results of both the primary and secondary stroke prevention trials in Nigeria suggest that neurological benefit can be achieved with fixed low-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         (10 mg/kg daily). However, based on the SPRING trial results, fixed moderate-dose hydroxyurea (20 mg/kg/day) should be used for children with frequent hospitalizations, increased rates of pain requiring a physician visit, or treatment at home. If hospitalization or vaso-occlusive pain events continue with the higher dose of hydroxyurea, we would consider maximum tolerated dose of hydroxyurea if the family can afford laboratory surveillance with frequent CBCs and the increase out-of-pocket expense for the hydroxyurea. (See
         <a class="local">
          'Dosing and monitoring'
         </a>
         below.)
        </p>
        <p>
         Primary and secondary stroke prevention in resource-rich settings is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">
          "Prevention of stroke (initial or recurrent) in sickle cell disease", section on 'Prevention of a first ischemic stroke (primary stroke prophylaxis)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">
          "Prevention of stroke (initial or recurrent) in sickle cell disease", section on 'Prevention of recurrent ischemic stroke (secondary stroke prophylaxis)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1433002237">
         <span class="h3">
          Access to stroke prevention interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         To our knowledge, none of the sub-Saharan African countries have extensive government-supported health insurance to pay for hospitalizations, radiology imaging, and medications such as
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         . (See
         <a class="local">
          'Hydroxyurea'
         </a>
         below.)
        </p>
        <p>
         Consequently, for the vast majority of children and adults with SCD in Africa, personal finances are the rate-limiting step to ensure evidenced-based medical care using evidence from randomized trials. In Nigeria, one of the wealthiest of the sub-Saharan African countries, 40 percent of the population lives on approximately USD $1.00 per day [
         <a href="#rid92">
          92
         </a>
         ]. In the northern region of Nigeria, the cost of a complete blood count is USD $5.00. Without state or federal government support that includes access to
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , a sustainable primary stroke prevention program with treatment will be unlikely.
        </p>
        <p>
         Given these challenges, government leaders of three northern Nigerian states with at least 40,000 children with SCD elected to provide
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         free of charge to children with abnormal TCD measurements or children with strokes [
         <a href="#rid93">
          93
         </a>
         ]. Further, TCD measurements are done without charge, and hydroxyurea is made available below cost for USD $0.15 from a Nigerian pharmaceutical company in which the corporate leadership acknowledges the humanitarian struggle of SCD in the region. The combination of state-supported stroke prevention programs for children with SCD coupled with access to low-cost hydroxyurea and streamlined laboratory monitoring has led to a significant increase in screening and treatment of children with SCD for primary and secondary stroke prevention [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6881882">
         <span class="h1">
          PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         With each passing year, more adolescents with SCD will reach childbearing age because of the increase in overall survival. Pregnancy in SCD is associated with higher rates of both maternal and fetal complications:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preconception counseling requires knowledge of sickle cell trait status, which in turn requires specific testing because carrier status is clinically silent. However, screening does not always translate into a reduced incidence of the disease [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal events include those associated with pregnancy such as eclampsia, anemia, and urinary tract infection; and those related to SCD, such as pulmonary complications and vaso-occlusive events (both antenatal and postnatal) [
         <a href="#rid96">
          96-98
         </a>
         ]. Greater need for cesarean delivery and greater maternal death rates are often seen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal complications include intrauterine growth restriction (IUGR), preterm delivery, fetal distress in labor, and low birth weight [
         <a href="#rid96">
          96-98
         </a>
         ]. Perinatal mortality rates are also increased.
        </p>
        <p>
        </p>
        <p>
         Prenatal counseling is appropriate if the hemoglobin phenotypes of both parents are known based on confirmed laboratory testing.
        </p>
        <p>
         A multidisciplinary team including a hematologist, obstetrician, midwives, nurses, anesthetist, and intensive care team should be involved in pregnancy care to manage these risks. Involving a multidisciplinary care team can significantly decrease the rates of maternal and perinatal mortality in pregnant women with SCD in low-resource settings [
         <a href="#rid99">
          99
         </a>
         ]. However, coordinated efforts are required to undertake this strategy.
        </p>
        <p>
         During routine antenatal care, counseling should include the increased risks of acute painful episodes and pregnancy complications, including fetal loss, intrauterine growth restriction, eclampsia, and preeclampsia. A more frequent schedule of care should be planned between the obstetrician, hematologist, and specialist midwives.
        </p>
        <p>
         All pregnant individuals should be given daily
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         and antimalarial prophylaxis. Iron supplementation may be required, but only if the serum ferritin levels are low.
        </p>
        <p>
         During each prenatal visit, the following should be monitored:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemoglobin level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal monitoring
        </p>
        <p>
        </p>
        <p>
         Fetal ultrasound testing is done frequently (eg, at 20, 26, 30, 34, and 38 weeks) and is the standard of care in major health facilities. Scans may be performed more frequently if there are concerns about fetal growth or the volume of amniotic fluid (also called liquor amnii), and umbilical artery Doppler scans may be added if appropriate.
        </p>
        <p>
         Blood transfusion (preferably exchange transfusion) should be used for the treatment of acute anemia (a decrease in hemoglobin by at least 2 g/dL from baseline) and for acute chest syndrome.
        </p>
        <p>
         Delivery is usually targeted for 38 weeks of gestation. The aim is to achieve a safe vaginal delivery. The mother should be well hydrated and oxygenated throughout labor. The fetus should be monitored throughout labor. Epidural anesthesia is preferable to general anesthesia if operative intervention is needed.
        </p>
        <p class="headingAnchor" id="H1806664">
         <span class="h1">
          CHRONIC COMPLICATIONS/ADULTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advances in technology and improvement in medical care has significantly increased the survival of children with SCD, resulting in a substantial proportion reaching adult age [
         <a href="#rid68">
          68,100
         </a>
         ]. Causes of morbidity in adults with SCD include complications associated with pregnancy and renal, pulmonary, and orthopedic complications [
         <a href="#rid101">
          101-104
         </a>
         ]. A multidisciplinary team approach to care is shown to be effective in the management of individuals with SCD (especially adults, who may develop these chronic complications) and is recommended as the best practice approach in caring for these individuals.
        </p>
        <p>
         A 2017 study of 2047 individuals living in sub-Saharan Africa evaluated the association between steady-state hemolysis and vascular complications of SCD [
         <a href="#rid105">
          105
         </a>
         ]. Similar to findings in high-income countries, anemia was associated with elevated tricuspid regurgitant jet (TRJ) velocity, microalbuminuria, and leg ulcers [
         <a href="#rid106">
          106,107
         </a>
         ]. Additionally, the authors emphasized that in Africa, the most common and important causes of severe anemia in SCD may be different from high-income countries, potentially including additional factors such as malnutrition (eg, iron deficiency) and infectious diseases such as malaria and helminth infestations.
        </p>
        <p class="headingAnchor" id="H6881965">
         <span class="h2">
          Complications affecting the kidney
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications affecting the kidney are common in SCD. As part of routine management of patients with SCD, urinalysis is recommended during every clinic visit at least twice a year to screen for hematuria and proteinuria.
        </p>
        <p>
         Hematuria, when it occurs, is mainly due to papillary necrosis. Management involves admission into the hospital, intravenous fluids (approximately 100 to 150 mL/kg daily for children and approximately 4 to 6 L/daily in adults).
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          Furosemide
         </a>
         is given to improve urine volume and reduce the risk of urinary tract obstruction from clots. Blood transfusion may be required if hematuria is severe.
        </p>
        <p>
         Optimal management of children and adults with kidney disease is not well established in low-middle or high-income settings. Preliminary data would indicate
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         may attenuate progressive albuminuria [
         <a href="#rid108">
          108-111
         </a>
         ]. Patients with persistent proteinuria or other nephropathy are usually referred to the nephrologist for expert evaluation and medical management to reduce the risk and/or progression of sickle nephropathy. (See
         <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">
          "Sickle cell disease effects on the kidney"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6881972">
         <span class="h2">
          Pulmonary complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary complications of SCD include pulmonary hypertension (PH) and asthma. Cardiopulmonary complications are among the most common complications in adults with SCD and among the leading causes of death in these individuals [
         <a href="#rid112">
          112,113
         </a>
         ]; yet, the capacity to adequately diagnose and manage these complications is still lacking in majority of centers in Africa.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PH
         </strong>
         – PH is one of the most common complications in adults with SCD, with a prevalence of about 6 to 10.5 percent [
         <a href="#rid114">
          114-116
         </a>
         ]. Previous studies showed that adults with PH have an increased risk for early death [
         <a href="#rid114">
          114-116
         </a>
         ]. One of the non-invasive methods for screening adults with SCD to determine those at risk of PH is the use of Doppler echocardiography to measure the tricuspid regurgitant velocity (TRV). Multiple studies demonstrated that increase in TRV &gt;2.5 m/s is associated with increased mortality in adults with SCD [
         <a href="#rid117">
          117,118
         </a>
         ]. A clinical practice guideline from the American Thoracic Society emphasized the benefits of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         therapy in reducing this risk [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">
          "Overview of the pulmonary complications of sickle cell disease", section on 'Pulmonary hypertension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         All adult patients with SCD should be screened annually with Doppler echocardiograph to determine the TRV, and all patients with a TRV &gt;2.5 m/s should be offered
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         as part of standard guidelines (see
         <a class="local">
          'Hydroxyurea'
         </a>
         below). However, this is a major challenge, as the majority of centers in Africa do not have access to echocardiography.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma and chronic lung disease
         </strong>
         – Chronic lung disease is defined by clinical, laboratory, and spirometry criteria [
         <a href="#rid119">
          119
         </a>
         ]. In adults, SCD alone is an independent risk factor for recurrent wheezing, acute chest syndrome, and respiratory death, and low forced expiratory volume on spirometry is an independent risk factor for death in adults with SCD [
         <a href="#rid119">
          119-123
         </a>
         ]. Based on these significant findings, we recommend that all patients with SCD should be asked about asthma symptoms, and all adults with SCD should have annual spirometry screening.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Those with symptoms or spirometry findings suggestive of asthma should receive standard asthma management interventions, including education, control of trigger factors and comorbid conditions, and pharmacologic therapy, as outlined in the tables for ages &lt;4 years  (
         <a class="graphic graphic_table graphicRef127785" href="/z/d/graphic/127785.html" rel="external">
          table 9
         </a>
         ), 4 to 11 years  (
         <a class="graphic graphic_table graphicRef127786" href="/z/d/graphic/127786.html" rel="external">
          table 10
         </a>
         ), and 12 years and older  (
         <a class="graphic graphic_table graphicRef127798" href="/z/d/graphic/127798.html" rel="external">
          table 11
         </a>
         ), and discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1806923">
         <span class="h2">
          Orthopedic complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic osteomyelitis is common in children with sickle cell disease. (See
         <a class="medical medical_review" href="/z/d/html/5919.html" rel="external">
          "Acute and chronic bone complications of sickle cell disease", section on 'Osteomyelitis and septic arthritis'
         </a>
         .)
        </p>
        <p>
         Orthopedic complications are one of the most common sources of long-term morbidity in adults with SCD, typically avascular necrosis of the head of the femur [
         <a href="#rid24">
          24
         </a>
         ]. The presentation is characterized by pain in the hips, limping, and progressive deformity of the hip joint. In low-income countries, management includes prolonged analgesics, which only provide temporal relief of pain. The standard treatment for these patients should include physical therapy and surgical interventions. In sub-Saharan Africa, only a few centers can provide surgical interventions; reasons include cost, inadequate staffing and personnel, and lack of expertise and equipment [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3381730068">
         <span class="h2">
          Priapism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Priapism is a major cause of SCD morbidity in males of all ages with SCD, including children, adolescents, and adults. The high prevalence of SCD in Africa has facilitated a better understanding of this complication.
        </p>
        <p>
         In a cross-sectional study involving 500 males with SCD and 250 controls without SCD, the prevalence of priapism with SCD was 33 percent, versus 2 percent in controls [
         <a href="#rid124">
          124
         </a>
         ]. Among the individuals with SCD-associated priapism, intermittent priapism episodes lasting &lt;4 hours (also called stuttering priapism) occurred in 73 percent; the remainder had major priapism events lasting ≥4 hours. Priapism events that lasted at least three days were associated with penis deformity. Due to shame, lack of knowledge about the onset of priapism, and paucity of effective medical treatment to prevent or actively treat priapism, one-half of the affected individuals never sought medical attention. Individuals with priapism experienced sadness, frustration, fear, depression, and exhaustion. They used a range of self-care strategies to abate priapism episodes including but not limited to exercise, shower or baths, or hot packs.
        </p>
        <p>
         We advise against using cold packs to the penis to relieve vaso-occlusive pain. We advise surgical aspiration for treating major episodes (at least two to four hours) of priapism and
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         for secondary prevention, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7143.html" rel="external">
          "Priapism and erectile dysfunction in sickle cell disease", section on 'Ischemic priapism: Acute management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7143.html" rel="external">
          "Priapism and erectile dysfunction in sickle cell disease", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H243062">
         <span class="h1">
          DISEASE-MODIFYING OR CURATIVE THERAPIES
         </span>
        </p>
        <p class="headingAnchor" id="H243231">
         <span class="h2">
          Hydroxyurea
         </span>
        </p>
        <p class="headingAnchor" id="H1723098595">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         has become the standard of care for reducing the risk of vaso-occlusive and other complications in children and adults with SCD in high-income countries, based on demonstration of its efficacy in reducing complications in all age groups (including infants). These benefits are summarized in the table  (
         <a class="graphic graphic_table graphicRef129652" href="/z/d/graphic/129652.html" rel="external">
          table 12
         </a>
         ). In high-income countries, hydroxyurea is administered in a maximum tolerated dose strategy that increases the dose until peripheral blood counts decrease. This approach requires intensive monitoring (clinical and laboratory) with frequent and ongoing dose adjustments. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease"
         </a>
         .)
        </p>
        <p>
         As discussed above, we use
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         in individuals with severe acute pain episodes (three or more severe episodes per year), acute chest syndrome requiring transfusion, primary stroke prevention, and secondary stroke prevention. (See
         <a class="local">
          'Vaso-occlusive events'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         does not worsen the risk of severe malaria and may in fact reduce the risk. (See
         <a class="local">
          'Rationale'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H704382538">
         <span class="h3">
          Dosing and monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dosing of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         can be done either by a fixed-dose or by dose titration to mild neutropenia (absolute neutrophil count [ANC] &lt;4000/microL, as done in the REACH and NOHARM MTD trials).
        </p>
        <p>
         If cost and ease of administration are a concern, fixed-dose is preferred because it requires less intensive monitoring. Doses are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children – 20 mg/kg/day (moderate-dose)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults – 15 mg/kg/day
        </p>
        <p>
        </p>
        <p>
         For primary stroke prevention in children, based on the results of the SPRING trial, fixed low-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         (10mg/kg/day) may be the initial recommended dose for children with abnormal transcranial Doppler (TCD) velocities who do not have other reasons to require moderate-dose hydroxyurea, such as frequent vaso-occlusive pain or acute chest syndrome [
         <a href="#rid89">
          89
         </a>
         ]. Our preference for low-dose rather than moderate-dose hydroxyurea is based on the evidence of efficacy for primary stroke prevention and lower costs (see
         <a class="local">
          'Primary and secondary prevention (stroke)'
         </a>
         above). If there is an increase in vaso-occlusive pain episodes at home or an increase in physician visits for pain, or an increase in all-cause hospitalizations, then increasing to 20mg/kg/day should be considered.
        </p>
        <p>
         To address the limitation of fixed capsule sizes with a fixed dose, we often provide intermittent or uneven doses to account for the 500 mg capsule size [
         <a href="#rid125">
          125
         </a>
         ]. As an example, for a seven-year-old child who weighs 15 kg, the total weekly dose would be 20 mg/kg/day x 15 kg x 7 days = 2100 mg. Using 500 mg capsules, this could be provided as one capsule on Monday, Wednesday, Friday, and Saturday.
        </p>
        <p>
         Laboratory surveillance is required to assess for cytopenias associated with
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         . Monitoring is done with a complete blood count (CBC) once every six months. This surveillance interval is based on evidence that a fixed-dose (low or moderate dose) is not associated with clinically significant myelosuppression and is practical in low-income settings [
         <a href="#rid70">
          70,126
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3260940480">
         <span class="h3">
          Rationale
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of dosing schedule for
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , between maximum tolerated dose (MTD) or fixed moderate-dose, should be based on shared decision between the patient, family/caregivers, and clinicians and should take into account available evidence regarding efficacy and safety.
        </p>
        <p>
         For individuals with a low rate of vaso-occlusive events, we prefer starting with fixed low-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , since this provides similar efficacy as fixed moderate dose hydroxyurea for primary stroke prevention (see
         <a class="local">
          'Primary and secondary prevention (stroke)'
         </a>
         above). If rates of vaso-occlusive events (vaso-occlusive pain, acute chest syndrome) are high, we increase the dose to fixed moderate-dose hydroxyurea (20 mg/kg/day).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children
         </strong>
         – Regardless of whether fixed low-dose or fixed moderate-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         is used, we are not strong advocates of routine hydroxyurea dose escalation (to maximum tolerated dose) in children for the following reasons:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Moderate-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         was shown to be effective in reducing and preventing morbidity associated with SCD. Specifically, the SCD team in northern Nigeria showed that moderate-dose hydroxyurea significantly decreased the incidence rates of stroke comparable with using chronic blood transfusion therapy. Fixed moderate-dose hydroxyurea was also associated with decreased uncomplicated pain requiring hospitalization when compared with a group of non-randomly allocated children with SCD who did not receive hydroxyurea. (See
         <a class="local">
          'Supporting evidence'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of fixed moderate-dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         is practical for the majority of the population in Nigeria and other regions of Africa, where the out-of-pocket cost of hydroxyurea, CBCs, or both, are prohibitive. As described above, fixed-dose hydroxyurea can be safely administered with twice-yearly CBCs [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="local">
          'Primary and secondary prevention (stroke)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults
         </strong>
         – Given the higher rates of symptomatic vaso-occlusive pain events in adults with SCD, our practice is to start all such individuals on fixed-moderate dose
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         and if continued SCD-related events to increase the dose to maximum tolerated dose after shared decision making. In many clinical situations, the perceived benefits of maximum tolerated dose hydroxyurea may be superior to fixed moderate-dose hydroxyurea for preventing the most common causes of hospitalization (pain and ACS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If prevention of vaso-occlusive pain and ACS is the primary focus of treatment, and the costs and inconvenience of laboratory surveillance is not prohibitive, then maximum tolerated dose therapy may be the best option. However, if family financial constraints and resources do not allow for routine laboratory evaluation (CBC every two to three months) as done in high-income countries, then the strong consideration should be given to fixed moderate-dose therapy.
        </p>
        <p>
        </p>
        <p>
         Clinical trials of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         in malaria-endemic areas suggest that, compared with controls, individuals taking hydroxyurea had a lower risk of malaria infection than controls (when neither group was receiving malaria prophylaxis), or similar risk of infection as controls (when both groups were receiving malaria prophylaxis) [
         <a href="#rid127">
          127-129
         </a>
         ]. An in vitro study of red blood cells (RBCs) from people with and without SCD found that hydroxyurea and similar drugs were able to reduce growth of
         <em>
          P. falciparum
         </em>
         , principally acting at the schizont stage [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1557896616">
         <span class="h3">
          Barriers to uptake of hydroxyurea
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         is not used as often in very young children in Africa as it is in high-resource countries, primarily due to concerns about the higher rate of mortality and life-threatening bacterial and malarial infection in affected individuals in Africa and the unknown effect of hydroxyurea therapy (eg, possible increased toxicity) in such a vulnerable group [
         <a href="#rid17">
          17,43,131-134
         </a>
         ]. However, these concerns are lessening as more data on the safety of hydroxyurea in Africa become available.
        </p>
        <p>
         Multiple barriers result in low
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         use in Africa, including poverty, the absence of a public health insurance program, and the lack of local production of hydroxyurea. Without state or federal support for purchasing hydroxyurea, there is limited opportunity for the majority of children and adults to start and continue hydroxyurea.
        </p>
        <p>
         Other barriers include the large absolute numbers of individuals with SCD (see
         <a class="local">
          'Public health burden of SCD'
         </a>
         above), the lack of clinicians trained in the use of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , the uncertainty regarding the benefits and risks in a resource-poor setting where routine monitoring of blood counts is not available, and the relatively high costs of visits for follow-up, laboratory testing, and other monitoring when compared with the per capita income. For example, in Nigeria 40 percent of the population live on $1.00 per day, and the cost of a CBC is at least $5.00, a cost equivalent to one week's salary. Approaches to overcoming these barriers are possible [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         The strategy to use maximum tolerated dose of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         is a reasonable approach, particularly in light of the evidence of decrease vaso-occlusive events. However, this strategy can only be used in individuals who are able to bear these costs and at clinics that have the capacity to provide this level of care.
        </p>
        <p class="headingAnchor" id="H1151399485">
         <span class="h3">
          Supporting evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the barriers to uptake of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , evidence from the trials discussed below demonstrates that hydroxyurea is effective in reducing serious complications in individuals in sub-Saharan Africa, with additional benefit from increasing the dose. We believe these data will lead to more widespread use of hydroxyurea.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NOHARM and NOHARM MTD
         </strong>
         – A double-blinded, placebo-controlled trial from 2017 (the NOHARM [Novel Use of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         in an African Region with Malaria] trial) randomly assigned 207 children ages one to four years (average age, two years) in malaria-endemic Uganda to receive hydroxyurea at a fixed-dose (20 mg/kg daily) or placebo for one year [
         <a href="#rid127">
          127
         </a>
         ]. Compared with controls, children treated with hydroxyurea had a lower rate of a composite endpoint that included vaso-occlusive pain, dactylitis, acute chest syndrome, splenic sequestration, or blood transfusion (69 versus 45 percent; p = 0.001). Overall mortality was low (&lt;1 event per 100 patient-years), and the use of hydroxyurea was not associated with an increased incidence of malaria or other serious adverse events. The desired effects of hydroxyurea on laboratory parameters were seen (eg, increased total hemoglobin and fetal hemoglobin concentrations) despite dosing that did not approach the maximum tolerated dose strategy used in high-income countries.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At the end of the NOHARM trial, all children were treated with one year of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         at a fixed-dose of 20 mg/kg daily (open label). This was extended to a new trial (NOHARM MTD), in which 187 participants were randomly assigned to continue this fixed-dose or to switch to dose-escalated hydroxyurea [
         <a href="#rid128">
          128
         </a>
         ]. In the dose-escalation arm (referred to as maximum tolerated dose [MTD]), the hydroxyurea dose was raised by 5 mg/kg every two months until a cytopenia occurred (eg, absolute neutrophil count &lt;1000/microL (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         ), absolute reticulocyte count &lt;80,000/microL, platelet count &lt;80,000/microL, or hemoglobin &lt;4 g/dL). Blinding was maintained as the children on the fixed-dose arm periodically had dose adjustments for weight gain. The mean MTD dose was 29.5 mg/kg daily, versus the fixed-dose of 19.2 mg/kg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The trial was stopped early (at one year) for benefit in the dose-escalation/MTD arm. Compared with the fixed-dose arm, children assigned to the dose-escalation arm had improvements in the following outcomes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Any sickle cell-related adverse event (105 versus 245; incidence rate ratio [IRR], 0.43, 95% CI 0.34-0.54)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vaso-occlusive pain (86 versus 200; IRR 0.43, 95% CI 0.34-0.56)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute chest syndrome or pneumonia (8 versus 30, IRR 0.27; 95% CI 0.11-0.56)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transfusions (34 versus 116; IRR 0.30, 95% CI 0.20-0.43)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hospitalizations (19 versus 90; IRR 0.21, 95% CI 0.13-0.34)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Therapy was well-tolerated on both arms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          REACH
         </strong>
         – A large study in 2018 demonstrated that
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         can be safely administered to children in Africa with dramatic clinical benefits. The REACH (Realizing Effectiveness Across Continents with Hydroxyurea) study enrolled 635 children with SCD in four sub-Saharan African countries (Angola, Democratic Republic of Congo, Kenya, and Uganda) to receive hydroxyurea at a fixed-dose of 15 or 20 mg/kg daily for six months, followed by dose escalation to maximum tolerated dose, defined in this study as mild bone marrow suppression (typically, an absolute neutrophil count [ANC] &lt;4000/microL (
         <a class="calc calc_professional" href="/z/d/html/13483.html" rel="external">
          calculator 1
         </a>
         )) [
         <a href="#rid135">
          135
         </a>
         ]. Major findings included the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Efficacy
         </strong>
         –
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         dramatically reduced vaso-occlusive and other sickle cell complications compared with pre-treatment parameters obtained at the time of screening. Examples of reductions in death and complications include the following (expressed per 100 patient-years):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Mortality – From 3.6 to 1.1 (incidence rate ratio [IRR] 0.30, 95% CI 0.10-0.88)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Total sickle cell-related complications – From 115 to 53 (IRR 0.47, 95% CI 0.38-0.57)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pain episodes – From 98 to 45 (IRR 0.45, 95% CI 0.37-0.56)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Acute chest syndrome – From 9 to 5 (IRR 0.55, 95% CI 0.28-1.05)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Stroke – From 1.8 to 0.7 (IRR 0.42, 95% CI 0.10-1.67)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Malaria – From 47 to 23 (IRR 0.49, 95% CI 0.37-0.66)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Non-malarial infections – From 143 to 90 (IRR 0.62, 95% CI 0.53-0.72)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Laboratory correlates included a mean increase in hemoglobin level of 1 g/dL and a mean increase in fetal hemoglobin (Hb F) of 12.5 percent. Transfusions were reduced from 43 to 14 per 100-patient years.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Safety
         </strong>
         – Therapy was well tolerated, with the expected hematologic toxicities used for dose adjustments. There were no significant increases in serious treatment-related adverse events.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adherence
         </strong>
         – At the three-year point, 94 percent of children were still participating in the study, and more than 98 percent of visits were completed. This adherence rate is better than many trials completed in high-resource countries, demonstrating the high level of motivation in this population.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing
         </strong>
         – Dose escalation after the first six months of treatment was done by increasing the daily dose by 2.5 to 5 mg/kg/day every two months until an ANC of &lt;4000/microL was reached. The mean MTD dose was 22.5 mg/kg/day (mean doses in different countries ranged from 18.9 to 25.3 mg/kg/day), and the mean time to reach this dose was 11 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SPRING
         </strong>
         – SPRING and other trials focused specifically on stroke prevention are discussed above. (See
         <a class="local">
          'Primary and secondary prevention (stroke)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         These trials document that tens of thousands of children with SCD in Africa might benefit from
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         therapy for preventing morbidity associated with the disease. We suggest hydroxyurea therapy, preferably in a clinical trial setting, for children and adults with indications described above, including frequent vaso-occlusive pain or acute chest syndrome, stroke, or high risk of stroke based on elevated transcranial Doppler (TCD) measurements. (See
         <a class="local">
          'Vaso-occlusive events'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H243291">
         <span class="h2">
          Blood transfusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally reserve blood transfusion for severe, life-threatening anemia and/or acute stroke management for patients with SCD in sub-Saharan Africa.
        </p>
        <p>
         Blood transfusion is used in the management and prevention of several complications of SCD in children and adults in resource-rich countries. However, transfusion presents major challenges in sub-Saharan Africa [
         <a href="#rid136">
          136
         </a>
         ]. These challenges include the unavailability of blood, the high cost associated with receiving blood transfusions, and in some areas a high risk of transfusion-associated infections [
         <a href="#rid79">
          79
         </a>
         ]. Moreover, the majority of medical centers in sub-Saharan Africa rely on family replacement donation, which carries a higher risk of bloodborne infections than voluntary donors [
         <a href="#rid137">
          137-139
         </a>
         ]. Other major difficulties that have been reported include red blood cell alloimmunization due to non-standardized blood banking systems and transfusion reactions [
         <a href="#rid140">
          140
         </a>
         ].
        </p>
        <p>
         In the few African centers where blood transfusion is available and chronic blood transfusion is practiced, the risk of iron overload and the exorbitant cost of iron chelation is not affordable to the majority of families [
         <a href="#rid140">
          140-142
         </a>
         ]. As an example, the estimated annual cost of conducting chronic blood transfusion including iron chelation for a single patient in the United States is often over USD $50,000, with even higher costs associated with the oral iron chelation [
         <a href="#rid142">
          142,143
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H243417">
         <span class="h2">
          Hematopoietic stem cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allogeneic hematopoietic stem cell transplantation (HSCT) is the only available cure for SCD [
         <a href="#rid144">
          144,145
         </a>
         ]. This involves replacing the patient's bone marrow hematopoietic stem cells containing the sickle mutation with hematopoietic stem cells containing a normal beta-globin genotype (either heterozygous or homozygous).
        </p>
        <p>
         HSCT is rarely performed in low-income countries in Africa, despite the advancements made in high-income countries. This disparity has been illustrated in several reports:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A review of the global use of HSCT for any condition cataloged the rates of HSCT worldwide and trends in use of HSCT over the period from 2006 to 2008 [
         <a href="#rid146">
          146
         </a>
         ]. This found that of 146,808 transplants performed over this period of time, only 3964 (2.7 percent) were performed in Africa and the eastern Mediterranean region. The majority were in the United Arab Emirates, Qatar, and Egypt.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first HSCT for SCD in Nigeria was conducted in 2011; this resulted in successful engraftment with normal hematologic parameters at two years of follow-up [
         <a href="#rid147">
          147
         </a>
         ]. However, only four successful transplants have been conducted subsequently.
        </p>
        <p>
        </p>
        <p>
         The challenges associated with setting up a transplant program in African countries have been highlighted by several authors [
         <a href="#rid147">
          147-153
         </a>
         ]. These include poverty, shortages of personnel, inadequate infrastructure, ineffective health insurance policies, substandard facilities, and poor/inadequate supportive care. The most pressing challenge is the use of pay-for-service HSCT for SCD that may occur in Africa or elsewhere, referred to as medical tourism. Our experience has been that patients receive nonprotocol or clinical trial-associated transplant and return back to their home location where there is often inadequate medical expertise or support for timely and necessary post-HSCT care [
         <a href="#rid154">
          154
         </a>
         ].
        </p>
        <p>
         Additional details regarding HSCT in SCD including preferred donor, stem cell source, conditioning regimen, graft-versus-host disease prophylaxis, and the possibility of incorporating gene therapy, are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">
          "Hematopoietic stem cell transplantation in sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1334488312">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/132604.html" rel="external">
          "Patient perspective: Sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432682665">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Over 300,000 babies with sickle cell disease (SCD) are born annually, the majority in sub-Saharan Africa. The world's SCD population is concentrated in three countries: Nigeria, India, and the Democratic Republic of Congo  (
         <a class="graphic graphic_figure graphicRef106077" href="/z/d/graphic/106077.html" rel="external">
          figure 1
         </a>
         ), where the disease affects up to 2 percent of the population and the carrier state (sickle cell trait) prevalence is as high as 10 to 30 percent. (See
         <a class="local">
          'Public health burden of SCD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Diagnosis of SCD early in life improves survival. Newborn screening to identify affected individuals before the development of complications is ideal. Most individuals in sub-Saharan Africa are diagnosed when they present with symptoms during childhood, at a mean age of two years. (See
         <a class="local">
          'Identifying individuals with SCD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bacterial infection
         </strong>
         – The risk of bacterial infection is dramatically increased in SCD, particularly in children &lt;5 years of age. The two major prophylactic interventions are vaccinations, especially against encapsulated organisms, and daily oral penicillin, at least until age five years. Patients should seek medical attention if they have fever, cough, chest pain, headache, nuchal rigidity, bone pain, or other signs of infection, and patients with these findings should be treated promptly with broad-spectrum antibiotics. (See
         <a class="local">
          'Bacterial infections'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malaria
         </strong>
         – Although the sickle mutation is somewhat protective against malaria, infection occurs and may be severe. Strategies for control and prevention of malaria include mosquito control, personal protection, and antimalarial prophylaxis. We prefer daily proguanil based on good compliance and low frequency of side effects. Treatment of malarial infections is described above. (See
         <a class="local">
          'Malaria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute vaso-occlusive events
         </strong>
         – Vaso-occlusive events including stroke, pain episodes, acute chest syndrome (ACS), and priapism cause significant morbidity and mortality. Management includes appropriate diagnostic evaluations, adequate pain control and hydration, and antibiotics when appropriate. For acute stroke, blood transfusion is used when possible. (See
         <a class="local">
          'Vaso-occlusive events'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease-modifying therapy
         </strong>
         –
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         is the main disease-modifying therapy for SCD; benefits are summarized in the table  (
         <a class="graphic graphic_table graphicRef129652" href="/z/d/graphic/129652.html" rel="external">
          table 12
         </a>
         ). We use hydroxyurea for children with a history of stroke or elevated transcranial Doppler (TCD) velocities, frequent severe pain episodes, or ACS requiring transfusions. Hydroxyurea can be administered at a fixed low-dose (10 mg/kg/day) or a fixed moderate-dose (20 mg/kg/day) with twice yearly complete blood count (CBC), or using dose escalation to a maximum tolerated dose, based on more frequently obtained CBC parameters.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fixed moderate-dose
         </strong>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         <strong>
          for frequent vaso-occlusive events or prior stroke
         </strong>
         – For individuals with frequent vaso-occlusive events (vaso-occlusive pain, ACS) or prior stroke, we suggest hydroxyurea at a fixed dose of 20 mg/kg/day with monitoring, rather than fixed low-dose or maximum tolerated dose hydroxyurea (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); this assumes the family can afford the costs and burdens of this therapy. (See
         <a class="local">
          'Hydroxyurea'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fixed low-dose
         </strong>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         <strong>
          for primary stroke prevention
         </strong>
         – For individuals who do not have frequent vaso-occlusive events and have not had a stroke but do have elevated TCD velocities, we suggest hydroxyurea at a fixed dose of 10 mg/kg/day (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Hydroxyurea'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Escalation to maximum tolerated dose
         </strong>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         <strong>
          or other approaches for selected individuals
         </strong>
         – For individuals with access to resources for more frequent monitoring and/or for whom continued complications occur with fixed-dose hydroxyurea, titration to an absolute neutrophil count (ANC) &lt;4000/microL (maximum tolerated dose) may also be used if the patient, family/caregivers, and clinicians believe this would improve care. Transfusions and hematopoietic cell transplant may be options for selected individuals. (See
         <a class="local">
          'Hydroxyurea'
         </a>
         above and
         <a class="local">
          'Blood transfusion'
         </a>
         above and
         <a class="local">
          'Hematopoietic stem cell transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – Pregnancy is managed by a multidisciplinary team to address maternal and fetal risks. Close monitoring is required.
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         is administered daily. (See
         <a class="local">
          'Pregnancy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7139.html" rel="external">
          "Sickle cell disease: Obstetric considerations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other information
         </strong>
         – Overviews of SCD management in resource-rich settings are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/14519.html" rel="external">
          "Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1051808837">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
        </p>
        <p>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges the extensive contributions of William C Mentzer, MD, to earlier versions of this and many other topic reviews.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Diallo D, Tchernia G. Sickle cell disease in Africa. Curr Opin Hematol 2002; 9:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med 2013; 10:e1001484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odame I. Perspective: we need a global solution. Nature 2014; 515:S10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piel FB, Williams TN. Subphenotypes of sickle cell disease in Africa. Blood 2017; 130:2157.
          </a>
         </li>
         <li class="breakAll">
          http://www.un.org/millenniumgoals/childhealth.shtml (Accessed on March 12, 2015).
         </li>
         <li class="breakAll">
          http://www.afro.who.int/index.php?option=com_docman&amp;task=doc_download&amp;gid=5436 (Accessed on March 13, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lomazzi M, Borisch B, Laaser U. The Millennium Development Goals: experiences, achievements and what's next. Glob Health Action 2014; 7:23695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tshilolo L, Kafando E, Sawadogo M, et al. Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: lessons from pilot studies. Public Health 2008; 122:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadima BT, Gini Ehungu JL, Ngiyulu RM, et al. High rate of sickle cell anaemia in Sub-Saharan Africa underlines the need to screen all children with severe anaemia for the disease. Acta Paediatr 2015; 104:1269.
          </a>
         </li>
         <li class="breakAll">
          http://www.unicef.org/infobycountry/nigeria_statistics.html (Accessed on November 27, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odunvbun ME, Okolo AA, Rahimy CM. Newborn screening for sickle cell disease in a Nigerian hospital. Public Health 2008; 122:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeant GR. Geography and the clinical picture of sickle cell disease. An overview. Ann N Y Acad Sci 1989; 565:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 2010; 1:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAuley CF, Webb C, Makani J, et al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood 2010; 116:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makani J, Komba AN, Cox SE, et al. Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood 2010; 115:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med 2011; 41:S398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranque B, Kitenge R, Ndiaye DD, et al. Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study. Lancet Haematol 2022; 9:e208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeant GR. Mortality from sickle cell disease in Africa. BMJ 2005; 330:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahimy MC, Gangbo A, Ahouignan G, et al. Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting. Blood 2003; 102:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akinyanju OO, Otaigbe AI, Ibidapo MO. Outcome of holistic care in Nigerian patients with sickle cell anaemia. Clin Lab Haematol 2005; 27:195.
          </a>
         </li>
         <li class="breakAll">
          Sickle-cell disease: A strategy for the WHO African region. WHO, 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smart LR, Hernandez AG, Ware RE. Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Semin Hematol 2018; 55:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ansong D, Akoto AO, Ocloo D, Ohene-Frempong K. Sickle cell disease: management options and challenges in developing countries. Mediterr J Hematol Infect Dis 2013; 5:e2013062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosse SD, Olney RS, Baily MA. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl Health Econ Health Policy 2005; 4:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988; 81:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies SC, Cronin E, Gill M, et al. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000; 4:i.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green NS, Zapfel A, Nnodu OE, et al. The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood Adv 2022; 6:6187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele C, Sinski A, Asibey J, et al. Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test. Am J Hematol 2019; 94:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oluwole EO, Adeyemo TA, Osanyin GE, et al. Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria-A pilot study. PLoS One 2020; 15:e0242861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakou Danho JB, Atiméré YN, Koné D, et al. Feasibility Study of the "HemoTypeSC" Test for the Rapid Screening of Sickle Cell Disease in Côte D'Ivoire. Adv Hematol 2021; 2021:8862039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segbena AY, Guindo A, Buono R, et al. Diagnostic accuracy in field conditions of the sickle SCAN® rapid test for sickle cell disease among children and adults in two West African settings: the DREPATEST study. BMC Hematol 2018; 18:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olupot-Olupot P, Connon R, Kiguli S, et al. A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa. Am J Hematol 2022; 97:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makani J, Cox SE, Soka D, et al. Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS One 2011; 6:e14699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           William BM, Corazza GR. Hyposplenism: a comprehensive review. Part I: basic concepts and causes. Hematology 2007; 12:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overturf GD. Infections and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis 1999; 14:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong WY, Overturf GD, Powars DR. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. Clin Infect Dis 1992; 14:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onwubalili JK. Sickle cell disease and infection. J Infect 1983; 7:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramakrishnan M, Moïsi JC, Klugman KP, et al. Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearson HA. Sickle cell anemia and severe infections due to encapsulated bacteria. J Infect Dis 1977; 136 Suppl:S25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatr Blood Cancer 2010; 55:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet 2009; 374:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donkor ES, Osei JA, Anim-Baidoo I, Darkwah S. Risk of Asymptomatic Bacteriuria among People with Sickle Cell Disease in Accra, Ghana. Diseases 2017; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obaro S. Pneumococcal infections and sickle cell disease in Africa: does absence of evidence imply evidence of absence? Arch Dis Child 2009; 94:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soothill G, Darboe S, Bah G, et al. Invasive bacterial infections in Gambians with sickle cell anemia in an era of widespread pneumococcal and hemophilus influenzae type b vaccination. Medicine (Baltimore) 2016; 95:e5512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel NG, Lindsey T, Strunk RC, DeBaun MR. Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis. Pediatr Blood Cancer 2010; 55:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitarães EL, Oliveira BM, Viana MB. Compliance with antibiotic prophylaxis in children with sickle cell anemia: a prospective study. J Pediatr (Rio J) 2008; 84:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King L, Ali S, Knight-Madden J, et al. Compliance with intramuscular penicillin prophylaxis in children with sickle cell disease in Jamaica. West Indian Med J 2011; 60:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming AF. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Rev 1989; 3:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konotey-Ahulu FI. Malaria and sickle-cell disease. Br Med J 1971; 2:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           WHO Expert Committee on Malaria. World Health Organ Tech Rep Ser 2000; 892:i.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eke FU, Anochie I. Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study. Curr Ther Res Clin Exp 2003; 64:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diop S, Soudré F, Seck M, et al. Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial. Ann Hematol 2011; 90:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olaosebikan R, Ernest K, Bojang K, et al. A Randomized Trial to Compare the Safety, Tolerability, and Effectiveness of 3 Antimalarial Regimens for the Prevention of Malaria in Nigerian Patients With Sickle Cell Disease. J Infect Dis 2015; 212:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004; :CD000363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konotey-Ahulu FI. Management of patients with sickle-cell disease. Lancet 1972; 2:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aluoch JR. Higher resistance to Plasmodium falciparum infection in patients with homozygous sickle cell disease in western Kenya. Trop Med Int Health 1997; 2:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adjei GO, Goka BQ, Enweronu-Laryea CC, et al. A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria. Malar J 2014; 13:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adjei GO, Kurtzhals JA, Rodrigues OP, et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J 2008; 7:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egunsola O, Oshikoya KA. Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review. Malar J 2013; 12:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owusu ED, Visser BJ, Nagel IM, et al. The interaction between sickle cell disease and HIV infection: a systematic review. Clin Infect Dis 2015; 60:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godeau B, Bachir D, Schaeffer A, et al. Severe pneumococcal sepsis and meningitis in human immunodeficiency virus-infected adults with sickle cell disease. Clin Infect Dis 1992; 15:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kourtis AP, Bansil P, Johnson C, et al. Children with sickle cell disease and human immunodeficiency virus-1 infection: use of inpatient care services in the United States. Pediatr Infect Dis J 2007; 26:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odera EB, Kwobah C, Stone G, et al. Sickle cell disease and HIV: a case highlighting management challenges for children in a resource-limited setting. J Int Assoc Provid AIDS Care 2014; 13:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stinson J, Naser B. Pain management in children with sickle cell disease. Paediatr Drugs 2003; 5:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makani J, Ofori-Acquah SF, Nnodu O, et al. Sickle cell disease: new opportunities and challenges in Africa. ScientificWorldJournal 2013; 2013:193252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oppong SA, Asare EV, Olayemi E, et al. Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting. Am J Hematol 2019; 94:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galadanci NA, Abdullahi SU, Ali Abubakar S, et al. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial. Am J Hematol 2020; 95:E247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith-Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004; 103:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Royal JE, Seeler RA. Hypertension, convulsions, and cerebral haemorrhage in sickle-cell anaemia patients after blood-transfusions. Lancet 1978; 2:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben Khaled M, Ouederni M, Mankai Y, et al. Prevalence and predictive factors of splenic sequestration crisis among 423 pediatric patients with sickle cell disease in Tunisia. Blood Cells Mol Dis 2020; 80:102374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powars D, Wilson B, Imbus C, et al. The natural history of stroke in sickle cell disease. Am J Med 1978; 65:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitchen L, Westmacott R, Friefeld S, et al. The pediatric stroke outcome measure: a validation and reliability study. Stroke 2012; 43:1602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider WH. History of blood transfusion in sub-saharan Africa. Transfus Med Rev 2013; 27:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev 2012; 26:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owusu-Ofori S, Temple J, Sarkodie F, et al. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 2005; 45:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chevalier MS, Kuehnert M, Basavaraju SV, et al. Progress Toward Strengthening National Blood Transfusion Services - 14 Countries, 2011-2014. MMWR Morb Mortal Wkly Rep 2016; 65:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faye BF, Sow D, Seck M, et al. Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country. Adv Hematol 2017; 2017:3518402.
          </a>
         </li>
         <li class="breakAll">
          National guideline for the control and management of sickle cell disease. Federal Republic of Nigeria; Federal Ministry of Health, Abuja, 2014.
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood 2016; 127:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galadanci NA, Umar Abdullahi S, Vance LD, et al. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol 2017; 92:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagunju I, Brown BJ, Oyinlade AO, et al. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea. Pediatr Blood Cancer 2019; 66:e27252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adegoke SA, Macedo-Campos RS, Braga JAP, et al. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy. J Stroke Cerebrovasc Dis 2018; 27:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galadanci NA, Abdullahi SU, Tabari MA, et al. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial. Pediatr Blood Cancer 2015; 62:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagunju I, Brown BJ, Sodeinde O. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort. Pediatr Blood Cancer 2015; 62:1587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdullahi SU, Jibir BW, Bello-Manga H, et al. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. Lancet Haematol 2022; 9:e26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv 2020; 4:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdullahi SU, Sunusi S, Abba MS, et al. Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. Blood 2023; 141:825.
          </a>
         </li>
         <li class="breakAll">
          Nigeria releases new report on poverty and inequality in country. Worldbank. Available at: https://www.worldbank.org/en/programs/lsms/brief/nigeria-releases-new-report-on-poverty-and-inequality-in-country (Accessed on June 04, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galadanci AA, Galadanci NA, Jibir BW, et al. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria. Am J Hematol 2019; 94:E305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghafuri DL, Abdullahi SU, Dambatta AH, et al. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework. J Pediatr Hematol Oncol 2022; 44:e56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeant G, Mallapaty S. Q&amp;A: healthy progress. Nature 2014; 515:S6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassell K. Pregnancy and sickle cell disease. Hematol Oncol Clin North Am 2005; 19:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koshy M. Sickle cell disease and pregnancy. Blood Rev 1995; 9:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008; 199:125.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asare EV, Olayemi E, Boafor T, et al. Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting. Am J Hematol 2017; 92:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lionnet F, Arlet JB, Bartolucci P, et al. [Guidelines for management of adult sickle cell disease]. Rev Med Interne 2009; 30 Suppl 3:S162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandhu MK, Cohen A. Aging in Sickle Cell Disease: Co-morbidities and New Issues in Management. Hemoglobin 2015; 39:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godeau B, Noël V, Habibi A, et al. [Sickle cell disease in adults: which emergency care by the internists?]. Rev Med Interne 2001; 22:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godeau B. [Emergencies in adults with sickle cell disease]. Bull Acad Natl Med 2004; 188:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubert M, Elion J, Tolo A, et al. Degree of anemia, indirect markers of hemolysis, and vascular complications of sickle cell disease in Africa. Blood 2017; 130:2215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minniti CP, Taylor JG 6th, Hildesheim M, et al. Laboratory and echocardiography markers in sickle cell patients with leg ulcers. Am J Hematol 2011; 86:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drawz P, Ayyappan S, Nouraie M, et al. Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC. Clin J Am Soc Nephrol 2016; 11:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tehseen S, Joiner CH, Lane PA, Yee ME. Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease. Pediatr Blood Cancer 2017; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zahr RS, Hankins JS, Kang G, et al. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia. Am J Hematol 2019; 94:E27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aygun B, Mortier NA, Smeltzer MP, et al. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol 2013; 88:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurin LP, Nachman PH, Desai PC, et al. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrol Dial Transplant 2014; 29:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonseca GH, Souza R, Salemi VM, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012; 39:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehari A, Gladwin MT, Tian X, et al. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 2012; 307:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladwin MT, Barst RJ, Gibbs JS, et al. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One 2014; 9:e99489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 2014; 189:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powars DR. Sickle cell anemia and major organ failure. Hemoglobin 1990; 14:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen RT, Madadi A, Blinder MA, et al. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. Am J Hematol 2011; 86:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glassberg JA, Chow A, Wisnivesky J, et al. Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity. Br J Haematol 2012; 159:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galadanci NA, Liang WH, Galadanci AA, et al. Wheezing is common in children with sickle cell disease when compared with controls. J Pediatr Hematol Oncol 2015; 37:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kassim AA, Payne AB, Rodeghier M, et al. Low forced expiratory volume is associated with earlier death in sickle cell anemia. Blood 2015; 126:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idris IM, Abba A, Galadanci JA, et al. Men with sickle cell disease experience greater sexual dysfunction when compared with men without sickle cell disease. Blood Adv 2020; 4:3277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chambers TM, Kahan S, Camanda JF, et al. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola. Pediatr Blood Cancer 2018; 65:e27365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opoka RO, Ndugwa CM, Latham TS, et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood 2017; 130:2585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           John CC, Opoka RO, Latham TS, et al. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med 2020; 382:2524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olupot-Olupot P, Tomlinson G, Williams TN, et al. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood 2023; 141:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safeukui I, Ware RE, Mohandas N, Haldar K. Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. Blood Adv 2023; 7:5970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeh EI, Teclaire NN. Prevalence of malaria parasitaemia and associated factors in febrile under-5 children seen in Primary Health Care Centres in Jos, North Central Nigeria. Niger Postgrad Med J 2008; 15:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambe JP, Mava Y, Chama R, et al. Clinical features of sickle cell anaemia in northern nigerian children. West Afr J Med 2012; 31:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezeonwu B, Chima O, Oguonu T, et al. Morbidity and mortality pattern of childhood illnesses seen at the children emergency unit of federal medical center, asaba, Nigeria. Ann Med Health Sci Res 2014; 4:S239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komba AN, Makani J, Sadarangani M, et al. Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya. Clin Infect Dis 2009; 49:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med 2019; 380:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagunju IA, Brown BJ, Sodeinde OO. Chronic blood transfusion for primary and secondary stroke prevention in Nigerian children with sickle cell disease: a 5-year appraisal. Pediatr Blood Cancer 2013; 60:1940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tagny CT, Mbanya D, Tapko JB, Lefrère JJ. Blood safety in Sub-Saharan Africa: a multi-factorial problem. Transfusion 2008; 48:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bates I, Manyasi G, Medina Lara A. Reducing replacement donors in Sub-Saharan Africa: challenges and affordability. Transfus Med 2007; 17:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mbanya DN, Tayou C. Blood safety begins with safe donations: update among blood donors in Yaounde, Cameroon. Transfus Med 2005; 15:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seck M, Senghor AB, Loum M, et al. Transfusion Practice, Post-Transfusion Complications and Risk Factors in Sickle Cell Disease in Senegal, West Africa. Mediterr J Hematol Infect Dis 2022; 14:e2022004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 2007; 47:1820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delea TE, Hagiwara M, Thomas SK, et al. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol 2008; 83:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLeod C, Fleeman N, Kirkham J, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess 2009; 13:iii.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110:2749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoury R, Abboud MR. Stem-cell transplantation in children and adults with sickle cell disease: an update. Expert Rev Hematol 2011; 4:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gratwohl A, Baldomero H, Gratwohl M, et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 2013; 98:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bazuaye N, Nwogoh B, Ikponmwen D, et al. First successful allogeneic hematopoietic stem cell transplantation for a sickle cell disease patient in a low resource country (Nigeria): a case report. Ann Transplant 2014; 19:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SO. Challenges to overcome in setting up Hematopoietic Stem Cell Transplantation in Nigeria. Ife Med J 2009; 15:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durosinmi MA OA. Stem cell transplantation. Nig J Health Sciences 2008; 8:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AA O. Recent advances in stem cell biology: implications for tropical hematology practice. Annals of Tropical Pathology 2011; 2:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AA O. Hematopoietic stem cell transplantation: prospects and challenges in Nigeria. Ann Ibadan Postgraduate Med 2006; 4:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akinsete A, DeBaun M, Kassim AA. Improving Post-Transplant Outcomes Following Allogeneic Hematopoietic Stem Cell Transplant for Sickle Cell Disease in a Low Resource Setting: Experience from a Dedicated Post-Transplant Clinic in Nigeria. Biology of Blood and Marrow Transplantation 2020; 3:S219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akinsete AM, DeBaun MR, Kassim AA. Sickle Cell Disease Post-Transplant Care Challenges in Nigeria: Systematic Institutional Neglect of Medical Tourism. Blood 2019; 134:4568.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 99489 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11844993" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23103089" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23874164" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25390135" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Perspective: we need a global solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29146819" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Subphenotypes of sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29146819" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Subphenotypes of sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29146819" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Subphenotypes of sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24560268" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The Millennium Development Goals: experiences, achievements and what's next.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18555498" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: lessons from pilot studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25982693" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : High rate of sickle cell anaemia in Sub-Saharan Africa underlines the need to screen all children with severe anaemia for the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25982693" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : High rate of sickle cell anaemia in Sub-Saharan Africa underlines the need to screen all children with severe anaemia for the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18486954" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Newborn screening for sickle cell disease in a Nigerian hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2476057" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Geography and the clinical picture of sickle cell disease. An overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21045822" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20530796" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19901265" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22099364" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Sickle cell disease in Africa: a neglected cause of early childhood mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35240076" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15731125" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mortality from sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702514" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15938726" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Outcome of holistic care in Nigerian patients with sickle cell anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15938726" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Outcome of holistic care in Nigerian patients with sickle cell anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30616806" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24363877" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Sickle cell disease: management options and challenges in developing countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16466275" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3368274" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Newborn screening for sickle cell disease: effect on mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11965279" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Protective effects of the sickle cell gene against malaria morbidity and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10840658" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36264096" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30290004" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33270733" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria-A pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33790971" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Feasibility Study of the "HemoTypeSC" Test for the Rapid Screening of Sickle Cell Disease in Côte D'Ivoire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30237894" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Diagnostic accuracy in field conditions of the sickle SCAN®rapid test for sickle cell disease among children and adults in two West African settings: the DREPATEST study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35147242" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358818" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17364987" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hyposplenism: a comprehensive review. Part I: basic concepts and causes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10079855" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Infections and immunizations of children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1600015" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6313809" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Sickle cell disease and infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20417415" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/330779" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Sickle cell anemia and severe infections due to encapsulated bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20232448" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Susceptibility to invasive bacterial infections in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19747721" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28933357" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Risk of Asymptomatic Bacteriuria among People with Sickle Cell Disease in Accra, Ghana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19414433" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pneumococcal infections and sickle cell disease in Africa: does absence of evidence imply evidence of absence?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27930540" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Invasive bacterial infections in Gambians with sickle cell anemia in an era of widespread pneumococcal and hemophilus influenzae type b vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20658630" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18688558" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Compliance with antibiotic prophylaxis in children with sickle cell anemia: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21942123" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Compliance with intramuscular penicillin prophylaxis in children with sickle cell disease in Jamaica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2650773" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The presentation, management and prevention of crisis in sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5556078" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Malaria and sickle-cell disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10892307" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : WHO Expert Committee on Malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24944408" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20694469" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25701866" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A Randomized Trial to Compare the Safety, Tolerability, and Effectiveness of 3 Antimalarial Regimens for the Prevention of Malaria in Nigerian Patients With Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15106149" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Insecticide-treated bed nets and curtains for preventing malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4116192" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Management of patients with sickle-cell disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9236824" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Higher resistance to Plasmodium falciparum infection in patients with homozygous sickle cell disease in western Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25236838" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18620577" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24175945" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25344542" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The interaction between sickle cell disease and HIV infection: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1520768" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Severe pneumococcal sepsis and meningitis in human immunodeficiency virus-infected adults with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17468650" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Children with sickle cell disease and human immunodeficiency virus-1 infection: use of inpatient care services in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24257463" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Sickle cell disease and HIV: a case highlighting management challenges for children in a resource-limited setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12662119" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pain management in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25143960" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Sickle cell disease: new opportunities and challenges in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30456766" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32510680" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14525777" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Epidemiology of human parvovirus B19 in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/82175" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Hypertension, convulsions, and cerebral haemorrhage in sickle-cell anaemia patients after blood-transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31670184" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Prevalence and predictive factors of splenic sequestration crisis among 423 pediatric patients with sickle cell disease in Tunisia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9414296" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Cerebrovascular accidents in sickle cell disease: rates and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/717414" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The natural history of stroke in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22474056" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The pediatric stroke outcome measure: a validation and reliability study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22981696" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : History of blood transfusion in sub-saharan Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21872426" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15660820" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26866413" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Progress Toward Strengthening National Blood Transfusion Services - 14 Countries, 2011-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28584527" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28584527" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758917" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Central nervous system complications and management in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28439953" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29797633" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29056404" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25399822" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25847050" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34971579" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32298430" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36322937" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36322937" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31423630" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34001783" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25390144" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Q&amp;A: healthy progress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16214651" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Pregnancy and sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8563517" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Sickle cell disease and pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18533123" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Morbidity associated with sickle cell disease in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28512745" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3086721" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19713011" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : [Guidelines for management of adult sickle cell disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26182337" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Aging in Sickle Cell Disease: Co-morbidities and New Issues in Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11402515" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : [Sickle cell disease in adults: which emergency care by the internists?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15584659" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : [Emergencies in adults with sickle cell disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28931524" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Degree of anemia, indirect markers of hemolysis, and vascular complications of sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21630312" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Laboratory and echocardiography markers in sickle cell patients with leg ulcers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26672090" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28612449" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30359463" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23255310" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24084325" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7517723" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10861320" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21732836" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : A hemodynamic study of pulmonary hypertension in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21778170" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22453563" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Mortality in adults with sickle cell disease and pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24988120" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24628312" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2101835" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Sickle cell anemia and major organ failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21809369" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22966893" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25197776" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Wheezing is common in children with sickle cell disease when compared with controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26261241" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Low forced expiratory volume is associated with earlier death in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32702096" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Men with sickle cell disease experience greater sexual dysfunction when compared with men without sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30051651" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21571150" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29051184" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32579813" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36375125" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37093647" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18575475" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Prevalence of malaria parasitaemia and associated factors in febrile under-5 children seen in Primary Health Care Centres in Jos, North Central Nigeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23208475" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Clinical features of sickle cell anaemia in northern nigerian children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25364596" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Morbidity and mortality pattern of childhood illnesses seen at the children emergency unit of federal medical center, asaba, Nigeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19514855" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Malaria as a cause of morbidity and mortality in children with homozygous sickle cell disease on the coast of Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30501550" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23956197" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Chronic blood transfusion for primary and secondary stroke prevention in Nigerian children with sickle cell disease: a 5-year appraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18713111" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Blood safety in Sub-Saharan Africa: a multi-factorial problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18067647" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Reducing replacement donors in Sub-Saharan Africa: challenges and affordability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16202054" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Blood safety begins with safe donations: update among blood donors in Yaounde, Cameroon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35070211" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Transfusion Practice, Post-Transfusion Complications and Risk Factors in Sickle Cell Disease in Senegal, West Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17880607" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Clinical and economic burden of infused iron chelation therapy in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17924547" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19068191" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17606762" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21668398" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Stem-cell transplantation in children and adults with sickle cell disease: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23508009" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24792997" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : First successful allogeneic hematopoietic stem cell transplantation for a sickle cell disease patient in a low resource country (Nigeria): a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Challenges to overcome in setting up Hematopoietic Stem Cell Transplantation in Nigeria
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Stem cell transplantation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Recent advances in stem cell biology: implications for tropical hematology practice
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Hematopoietic stem cell transplantation: prospects and challenges in Nigeria
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20424252" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Hematopoietic stem cell transplantation: a global perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Improving Post-Transplant Outcomes Following Allogeneic Hematopoietic Stem Cell Transplant for Sickle Cell Disease in a Low Resource Setting: Experience from a Dedicated Post-Transplant Clinic in Nigeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Sickle Cell Disease Post-Transplant Care Challenges in Nigeria: Systematic Institutional Neglect of Medical Tourism
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
